NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Merck characterizes the measure, "tissue tumor mutational burden-high," or TMB-H, as tumors with at least 10 mutations per megabase or greater, which would be determined via an FDA-approved test. And Merck, incidentally, is leaning on evidence from the same Keynote-158 study that led to its first tissue-agnostic approval in 2017. Updated evidence from the study last year showed higher response rates to Keytruda for people with TMB-high tumors than others.

Replace tumor mutational burden with SUB-TYPE and Direct is
Good to Go .......